within Pharmacolibrary.Drugs.S_SensoryOrgans.S01E_AntiglaucomaPreparationsAndMiotics.S01EE03_Bimatoprost;

model Bimatoprost
  extends Pharmacolibrary.Drugs.ATC.S.S01EE03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>S01EE03</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Bimatoprost is a synthetic prostamide analog used primarily to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It is approved for ophthalmic use and is widely prescribed today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following topical ocular administration.</p><h4>References</h4><ol><li><p>Shafiee, A, et al., &amp; Hosseini, K (2013). Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes. <i>Clinical ophthalmology (Auckland, N.Z.)</i> 7 1549–1556. DOI:<a href=&quot;https://doi.org/10.2147/OPTH.S48766&quot;>10.2147/OPTH.S48766</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23940414/&quot;>https://pubmed.ncbi.nlm.nih.gov/23940414</a></p></li><li><p>Shen, J, et al., &amp; Attar, M (2017). Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications. <i>Clinical ophthalmology (Auckland, N.Z.)</i> 11 1761–1767. DOI:<a href=&quot;https://doi.org/10.2147/OPTH.S143428&quot;>10.2147/OPTH.S143428</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29026287/&quot;>https://pubmed.ncbi.nlm.nih.gov/29026287</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Bimatoprost;
